FDA Inspection 1329952 — Zhejiang StarryApex Biotechnology Co., Ltd.
The FDA completed an inspection of Zhejiang StarryApex Biotechnology Co., Ltd. on Jun 24, 2026 in Huzhou. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI)
- End Date
- Jun 24, 2026
- Fiscal Year
- 2026
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Huzhou (China)